Laurus Labs Q1 FY27 consolidated revenue Rs 2,026 Cr, PAT Rs 368 Cr
Laurus Labs’ consolidated Q1 FY27 revenue rose to Rs 2,026 Cr from Rs 1,570 Cr, with net profit up to Rs 368 Cr from Rs 163 Cr.
Key takeaways
- Revenue: Rs 2,026 crore in 1Q FY27 vs Rs 1,570 crore in 1Q FY26.
- EBITDA: Rs 644 crore in 1Q FY27 vs Rs 389 crore in 1Q FY26.
- EBITDA margin: 31.8% in 1Q FY27 vs 24.8% in 1Q FY26.
- Net Profit: Rs 368 crore in 1Q FY27 vs Rs 163 crore in 1Q FY26.
- EPS: 6.8 in 1Q FY27 vs 3.0 in 1Q FY26, as per the financial summary.
Q1 FY27 · consolidated
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | Rs 2,026 crore | Rs 1,570 crore | +29.0% |
| PAT | Rs 368 crore | Rs 163 crore | +126.0% |
| Margin | 18.2% | 10.4% | +7.8% |
As reported in the filing. Figures are transcribed, not computed.
• Basis: Consolidated statement of financial results, quarter ended 30 June 2026 (Q1 FY27), compared with quarter ended 30 June 2025 (Q1 FY26), as presented in the 1Q FY27 Financial Summary table in the investor presentation.
• Revenue from operations ("Revenue"): Rs 2,026 crore in 1Q FY27, vs Rs 1,570 crore in 1Q FY26.
• EBITDA: Rs 644 crore in 1Q FY27, vs Rs 389 crore in 1Q FY26.
• EBITDA margin (% to Revenue): 31.8% in 1Q FY27, vs 24.8% in 1Q FY26.
• Net Profit: Rs 368 crore in 1Q FY27, vs Rs 163 crore in 1Q FY26.
• Net Profit margin (% to Revenue): 18.2% in 1Q FY27, vs 10.4% in 1Q FY26.
• EPS (Rs): 6.8 in 1Q FY27, vs 3.0 in 1Q FY26.
According to the 1Q FY27 Financial Summary table in the investor presentation, Laurus Labs reported consolidated Revenue of Rs 2,026 crore for the quarter ended 30 June 2026, up from Rs 1,570 crore in the corresponding quarter ended 30 June 2025. The company’s commentary in the same section attributes the 29% increase in Revenue primarily to "robust CDMO growth supported by sustained Affordable Medicine business (led by FDF)."
EBITDA rose to Rs 644 crore in 1Q FY27 from Rs 389 crore in 1Q FY26. The EBITDA margin, shown as "% to Revenue" in the table, improved to 31.8% in 1Q FY27 from 24.8% in 1Q FY26. In the accompanying notes to the table, the company states that EBITDA margins increased "due to favorable product mix and improving operational leverage."
Net Profit for the quarter increased to Rs 368 crore in 1Q FY27 from Rs 163 crore in 1Q FY26. The Net Profit margin, again shown as "% to Revenue" in the same table, moved to 18.2% in 1Q FY27 from 10.4% in 1Q FY26. The company notes that Net Profit increased 126% year-on-year.
The 1Q FY27 Financial Summary also discloses that EPS (Rs) was 6.8 in 1Q FY27, compared with 3.0 in 1Q FY26. In the comments alongside the table, Laurus Labs reports that R & D spends were Rs 118 crore (5.8% of Revenue) in 1Q FY27, including Capex R&D spends of Rs 35 crore towards Advanced Biologics (Gene therapy and ADC).
Track Laurus Labs Ltd
Cruxal reads every Laurus Labs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
